The FDA and biotech company Genentech have revised the safety warnings for the psoriasis drug Raptiva. The revisions include a new warning about a type of anemia called immune-mediated hemolytic ...

Genentech Inc. is pulling its 5-year-old psoriasis treatment Raptiva off the U.S. market because of links to a fatal brain infection. The move comes only six months after the company updated the ...

Swiss biotechnology company Serono has decided to undertake a major post-marketing study of its psoriasis drug Raptiva in Europe to try to lay to rest safety fears about the drug, recently raised by ...

Genentech and FDA announced the withdrawal of psoriasis treatment Raptiva due to a risk of progressive multifocal leukoencephalopathy (PML), a rare and deadly viral brain infection. The agency added a ...

WASHINGTON, April 9 (UPI) -- The U.S. Food and Drug Administration says Genentech Inc. is withdrawing the psoriasis drug Raptiva and it will no longer be available in the United States. The FDA said ...

WASHINGTON (CNN)-- The government is warning that taking the psoriasis drug Raptiva could result in serious brain infection and even death. The Food and Drug Administration cited three confirmed cases ...

GENEVA, Switzerland, February 19 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the European Medicines Agency (EMEA) has recommended to the European ...

A medical advisory panel Tuesday recommended Food and Drug Administration approval of Raptiva, bringing Genentech Inc. closer to entering the coveted market for psoriasis drugs. The expert committee ...

Genentech, Inc. and XOMA Ltd. today announced positive results from a randomized Phase III clinical trial with Raptiva TM (efalizumab) that studied efficacy and safety in the treatment of adults with ...

Genentech Inc. and Xoma Ltd. said Raptiva, their drug for the skin disorder psoriasis, failed in a study to ease symptoms of a related form of arthritis. Shares of both companies fell, with Xoma down ...

WASHINGTON, Feb 19 (Reuters) - Sales of Merck KGaA's psoriasis drug Raptiva should be suspended in light of serious brain infections confirmed in three patients, European authorities recommended on ...